Adjuvant therapy in renal cell carcinoma—is pharmacogenomics assessment another element to select our patients?

Vincenzo Di Nunno; Veronica Mollica; Lidia Gatto; Matteo Santoni; Giulia Sorgentoni; Nicola Battelli; Francesco Massari

doi:10.21037/atm.2019.02.31

Editorial Commentary

Adjuvant therapy in renal cell carcinoma—is pharmacogenomics assessment another element to select our patients?

Vincenzo Di Nunno, Veronica Mollica, Lidia Gatto, Matteo Santoni, Giulia Sorgentoni, Nicola Battelli, Francesco Massari

Abstract

Adjuvant therapy in resected renal cell carcinoma (RCC) is a discussed and complex issue due to conflicting results obtained in several clinical trials exploring different agents in this setting (1-4).

Editorial Commentary

Adjuvant therapy in renal cell carcinoma—is pharmacogenomics assessment another element to select our patients?

Abstract

Article Options

Download Citation

Share